Sartorius stock gains on 2.43 percent rise and earnings base
Published on 09/20/2026 at 11:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Sartorius stock (ISIN DE0007165631) finished Xetra trading at EUR 248.30 on September 18, 2026, up 2.43 percent on the day. The German life-sciences group also pointed to first-half 2026 revenue of EUR 1.77 billion and an EBITDA margin of 29.5 percent, which gives the move a clear operating backdrop.
Price strength near the session close
According to ad hoc news on September 19, 2026, the stock finished Xetra trading at EUR 248.30, 2.43 percent above the prior close. That puts the share near the upper end of its recent range and keeps price action tied to valuation rather than a single event.
For investors, the number that matters is not only the daily gain. It is the combination of EUR 248.30 on September 18, 2026, the 2.43 percent rise and the 29.5 percent EBITDA margin in first-half 2026.
Revenue and margin base
According to Sartorius in its first-half 2026 reporting, revenue reached EUR 1.77 billion and the EBITDA margin stood at 29.5 percent. Those figures matter because they show that the share price is resting on a business that is still producing a high operating margin.
The comparison is concrete: the first-half 2026 margin of 29.5 percent is the metric the market now measures against prior periods, while revenue of EUR 1.77 billion anchors the earnings base. In a stock like Sartorius, that mix usually matters more than a short burst in trading.
What the chart says
The latest quoted move leaves Sartorius stock with a dated reference point: EUR 248.30 on September 18, 2026. That is the level to watch against the next trading sessions, especially after the 2.43 percent daily gain.
Sartorius stock at a glance
- Company: Sartorius AG
- ISIN: DE0007165631
- Ticker: SRT3
- Trading venue: Xetra
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: DAX
